Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,730 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
Murray M, Antela A, Mills A, Huang J, Jäger H, Bernal E, Lombaard J, Katner H, Walmsley S, Khuong-Josses MA, Hudson K, Dorey D, Griffith S, Spreen W, Vanveggel S, Shaefer M, Margolis D, Chounta V. Murray M, et al. AIDS Behav. 2020 Dec;24(12):3533-3544. doi: 10.1007/s10461-020-02929-8. AIDS Behav. 2020. PMID: 32447500 Free PMC article.
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.
Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, Swindells S, Bredeek UF, García Del Toro M, Garcia Gasalla M, Rubio García R, Antela A, Hudson K, Griffith S, Kerrigan D. Mantsios A, et al. Among authors: murray m. AIDS Behav. 2020 Dec;24(12):3473-3481. doi: 10.1007/s10461-020-02918-x. AIDS Behav. 2020. PMID: 32410051 Clinical Trial.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, Lutz T, Angel JB, Richmond GJ, Clotet B, Gutierrez F, Sloan L, Clair MS, Murray M, Ford SL, Mrus J, Patel P, Crauwels H, Griffith SK, Sutton KC, Dorey D, Smith KY, Williams PE, Spreen WR. Margolis DA, et al. Among authors: murray m. Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24. Lancet. 2017. PMID: 28750935 Clinical Trial.
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
Murray M, Pulido F, Mills A, Ramgopal M, LeBlanc R, Jaeger H, Canon V, Dorey D, Griffith S, Mrus J, Spreen W, Margolis D. Murray M, et al. HIV Res Clin Pract. 2019 Aug-Oct;20(4-5):111-122. doi: 10.1080/25787489.2019.1661696. Epub 2019 Sep 18. HIV Res Clin Pract. 2019. PMID: 31533539 Free article. Clinical Trial.
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
Murray MI, Markowitz M, Frank I, Grant RM, Mayer KH, Hudson KJ, Stancil BS, Ford SL, Patel P, Rinehart AR, Spreen WR, Margolis DA. Murray MI, et al. HIV Clin Trials. 2018 Aug;19(4):129-138. doi: 10.1080/15284336.2018.1511346. Epub 2018 Nov 16. HIV Clin Trials. 2018. PMID: 30445896 Free article. Clinical Trial.
Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States.
Kerrigan D, Mantsios A, Grant R, Markowitz M, Defechereux P, La Mar M, Beckham SW, Hammond P, Margolis D, Murray M. Kerrigan D, et al. Among authors: murray m. AIDS Behav. 2018 Nov;22(11):3540-3549. doi: 10.1007/s10461-017-2017-x. AIDS Behav. 2018. PMID: 29290075 Free PMC article.
"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain.
Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, Swindells S, Bredeek UF, Deltoro MG, García RR, Antela A, Garris C, Shaefer M, Gomis SC, Bernáldez MP, Kerrigan D. Mantsios A, et al. Among authors: murray m. Cult Health Sex. 2021 Aug;23(8):1066-1078. doi: 10.1080/13691058.2020.1752397. Epub 2020 May 21. Cult Health Sex. 2021. PMID: 32436478
Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial.
Kerrigan D, Murray M, Sanchez Karver T, Mantsios A, Walters N, Hudson K, Kaplan-Lewis E, Pulido F, Bassa AC, Margolis D, Galai N. Kerrigan D, et al. Among authors: murray m. AIDS Res Hum Retroviruses. 2021 Mar;37(3):207-213. doi: 10.1089/AID.2020.0208. Epub 2021 Jan 19. AIDS Res Hum Retroviruses. 2021. PMID: 33323029 Clinical Trial.
Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.
Mantsios A, Murray M, Karver TS, Davis W, Galai N, Kumar P, Swindells S, Bredeek UF, García RR, Antela A, Gomis SC, Bernáldez MP, Czarnogorski M, Hudson K, Walters N, Kerrigan D. Mantsios A, et al. Among authors: murray m. BMC Health Serv Res. 2021 Mar 20;21(1):255. doi: 10.1186/s12913-021-06214-9. BMC Health Serv Res. 2021. PMID: 33743684 Free PMC article. Clinical Trial.
4,730 results